Alnylam reports positive vutrisiran data in hATTR amyloidosis with polyneuropathy at 18 months

28 October 2021

US biotech Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced new data from the HELIOS-A Phase III study of vutrisiran, an investigational RNAi therapeutic in development for the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis.

This study met all secondary endpoints measured at 18 months, including statistically-significant improvements in neuropathy as measured by the modified neuropathy impairment score, quality of life, gait speed, nutritional status and overall disability, relative to external placebo data from the APOLLO Phase III study of patisiran.

Continuation of success seen at nine months

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK